WAY-620521 is an active molecule.

WAY-607695 is an active molecule.

Nurr1 agonist 7 (compound 110) is a Nurr1 agonist with an EC50 value of 0.12 μM.

Nurr1 agonist 8 (compound 111) is a Nurr1 agonist with an EC50 value of 0.09 μM.

WAY-221060-A is an active molecule.

Anti-inflammatory agent 63 is an anti-inflammatory agent that shows optimal inhibitory activity (EC50 = 5.33±0.57 μM) against the production of nitric oxide (NO) induced by lipopolysaccharide (LPS) in RAW264.7 cells.

WAY-639872 is an active molecule.

WAY-215718 is an active molecule.

WAY-328127 is an active molecule.

WAY-616296 is an active molecule.

WAY-325811 is an active molecule.

WAY-649123 is an active molecule.

Tyrosinase-IN-17 (Compound 5b) is a lipophilic, skin-permeable, and non-cytotoxic Tyrosinase inhibitor (pIC50=4.99). Tyrosinase-IN-17 can be used for research on melanin-related diseases, such as melanoma, melanogenesis, etc.

Aβ42 agonist-1 (compound 7a) is a small molecule compound that can promote Aβ42 aggregation. Aβ42 agonist-1 can interact with Aβ42 oligomers and pentamers to promote nontoxic aggregate self-assembly and rapid fibril formation. Aβ42 agonist-1 prevents Aβ42-induced cytotoxicity in HT22 hippocampal neuronal cells.

Aurora kinase inhibitor-11 (compound 25) is an inhibitor of Aurora Kinase with an IC50 of 0.14 μM. Aurora kinase inhibitor-11 has anticancer activity.

Aβ42 agonist-2 (compound 7b) is a small molecule compound that can promote Aβ42 aggregation. Aβ42 agonist-2 can interact with Aβ42 oligomers and pentamers to promote nontoxic aggregate self-assembly and rapid fibril formation. Aβ42 agonist-2 prevents Aβ42-induced cytotoxicity in HT22 hippocampal neuronal cells.

ATG12-ATG3 inhibitor 1 (compound 189) is a potent inhibitor of autophage.

hCAI/II-IN-7 (compound 1F) is a potent carbonic anhydrase (CA) inhibitor with Ki values of 23 nM, 44 nM and 20.57 µM for hCA-I, hCA-II and bovine CA, respectively.

HDAC6-IN-27 (compound 8C) is a HDAC inhibitor with IC50 vales of 15.9 nM 136.5 nM and 6180.2 nM for HDAC6, HDAC8 and HDAC1, respectively. HDAC6-IN-27 shows potent antiparasitic effects.

AN-12-H5 intermediate-3 is an intermediate of the viral inhibitor AN-12-H5 (HY-120900) and can be used to synthesize Antibody-Drug Conjugates (ADCs).

Anti-osteoporosis agent-6 (compound 174) is an anti-osteoporosis agent. Anti-osteoporosis agent-6 has 14.11% inhibition rate against osteoclast formation at 10 μM.

Anti-osteoporosis agent-5 (compound 189) is a potent inhibitor of the formation of osteoclasts.